Article
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Haematologica - 1 Mar 2017
Scharenberg Christian, Giai Valentina, Pellagatti Andrea, Saft Leonie, Dimitriou Marios, Jansson Monika, Jädersten Martin, Grandien Alf, Douagi Iyadh, Neuberg Donna S, LeBlanc Katarina, Boultwood Jacqueline, Karimi Mohsen, Jacobsen Sten Eirik W, Woll Petter S, Hellström-Lindberg Eva
Abstract excerpt
A high proportion of patients with lower-risk del(5q) myelodysplastic syndromes will respond to treatment with lenalidomide. The median duration of transfusion-independence is 2 years with some long-lasting responses, but almost 40% of patients progress to acute leukemia by 5 years after starting treatment. The mechanisms underlying disease progression other than the well-established finding of small TP53-mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.